Gustave Roussy, Université Paris-Saclay, Inserm U1030, Villejuif, France.
Labex LERMIT, DHU TORINO, SIRIC SOCRATE.
Eur Respir J. 2018 Mar 1;51(3). doi: 10.1183/13993003.02120-2017. Print 2018 Mar.
Radiation-induced lung fibrosis (RIF) is a delayed side-effect of chest radiotherapy, frequently associated with macrophage infiltration.We aimed to characterise the role of pulmonary macrophages in RIF using human lung biopsies from patients receiving radiotherapy for thorax malignancies and a RIF model developed in C57BL/6 mice after 16-Gy thorax irradiation.High numbers of macrophages (both interstitial and alveolar) were detected in clinical and preclinical RIF. In the preclinical model, upregulation of T-helper (Th)2 cytokines was measured, whereas Th1 cytokines were downregulated in RIF tissue lysate. Bronchoalveolar lavage demonstrated upregulation of both types of cytokines. At steady state, tissue-infiltrating macrophages (IMs) expressed 10-fold more arginase (Arg)-1 than alveolar macrophages (AMs), and a 40-fold upregulation of Arg-1 was found in IMs isolated from RIF. IMs, but not AMs, were able to induce myofibroblast activation In addition, whereas depletion of AMs using Clodrosome didn't affect RIF score, depletion of IMs using a clinically available colony-stimulating factor receptor-1 (CSF1R) neutralising antibody was antifibrotic.These findings suggest differential contributions of alveolar interstitial macrophages in RIF, highlighting the fibrogenic role of IMs. The CSF1/CSF1R pathway was identified as a new therapeutic target to inhibit RIF.
放射性肺纤维化(RIF)是胸部放射治疗的一种迟发性副作用,常伴有巨噬细胞浸润。我们旨在通过对接受胸部恶性肿瘤放射治疗的患者的人肺活检和 16-Gy 胸部照射后 C57BL/6 小鼠的 RIF 模型,来描述肺巨噬细胞在 RIF 中的作用。在临床和临床前 RIF 中均检测到大量(间质和肺泡)巨噬细胞。在临床前模型中,测量到 Th2 细胞因子的上调,而 RIF 组织裂解物中 Th1 细胞因子下调。支气管肺泡灌洗显示两种细胞因子均上调。在稳定状态下,组织浸润巨噬细胞(IMs)表达的精氨酸酶(Arg)-1 比肺泡巨噬细胞(AMs)多 10 倍,而从 RIF 中分离的 IMs 中 Arg-1 的上调则高达 40 倍。IMs 而不是 AMs 能够诱导肌成纤维细胞的激活。此外,尽管使用 Clodrosome 耗尽 AMs 不会影响 RIF 评分,但使用临床可用的集落刺激因子受体-1(CSF1R)中和抗体耗尽 IMs 则具有抗纤维化作用。这些发现表明肺泡间巨噬细胞在 RIF 中的贡献不同,突出了 IMs 的致纤维化作用。CSF1/CSF1R 途径被确定为抑制 RIF 的新治疗靶点。